Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications

被引:13
作者
Chang, Lin-Chau [1 ]
Mahmood, Riaz [1 ,2 ]
Qureshi, Samina [1 ,3 ]
Breder, Christopher D. [1 ,4 ]
机构
[1] Johns Hopkins Univ, Master Sci Regulatory Sci Program, Adv Acad Programs, Krieger Sch Arts & Sci, Rockville, MD 20850 USA
[2] Campbell Univ, Sch Osteopath Med, Lillington, NC USA
[3] PSI Int Inc, Healthcare Pharma, Fairfax, VA USA
[4] US FDA, DNP, ODE1, OND,CDER, Silver Spring, MD 20993 USA
来源
PLOS ONE | 2017年 / 12卷 / 06期
关键词
RETRIEVAL; TERMS;
D O I
10.1371/journal.pone.0178104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose Standardised MedDRA Queries (SMQs) have been developed since the early 2000's and used by academia, industry, public health, and government sectors for detecting safety signals in adverse event safety databases. The purpose of the present study is to characterize how SMQs are used and the impact in safety analyses for New Drug Application (NDA) and Biologics License Application (BLA) submissions to the United States Food and Drug Administration (USFDA). Methods We used the PharmaPendium database to capture SMQ use in Summary Basis of Approvals (SBoAs) of drugs and biologics approved by the USFDA. Characteristics of the drugs and the SMQ use were employed to evaluate the role of SMQ safety analyses in regulatory decisions and the veracity of signals they revealed. Results A comprehensive search of the SBoAs yielded 184 regulatory submissions approved from 2006 to 2015. Search strategies more frequently utilized restrictive searches with "narrow terms" to enhance specificity over strategies using "broad terms" to increase sensitivity, while some involved modification of search terms. A majority (59%) of 1290 searches used descriptive statistics, however inferential statistics were utilized in 35% of them. Commentary from reviewers and supervisory staff suggested that a small, yet notable percentage (18%) of 1290 searches supported regulatory decisions. The searches with regulatory impact were found in 73 submissions (40% of the submissions investigated). Most searches (75% of 227 searches) with regulatory implications described how the searches were confirmed, indicating prudence in the decision-making process. Conclusions SMQs have an increasing role in the presentation and review of safety analysis for NDAs/BLAs and their regulatory reviews. This study suggests that SMQs are best used for screening process, with descriptive statistics, description of SMQ modifications, and systematic verification of cases which is crucial for drawing regulatory conclusions.
引用
收藏
页数:14
相关论文
共 17 条
  • [1] [Anonymous], 2016, GUID ATC CLASS DDD A
  • [2] Bill Robert W, 2012, AMIA Annu Symp Proc, V2012, P43
  • [3] Application of Information Retrieval Approaches to Case Classification in the Vaccine Adverse Event Reporting System
    Botsis, Taxiarchis
    Woo, Emily Jane
    Ball, Robert
    [J]. DRUG SAFETY, 2013, 36 (07) : 573 - 582
  • [4] A Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries
    Breder, Christopher D.
    [J]. PHARMACEUTICAL MEDICINE, 2016, 30 (02) : 103 - 108
  • [5] Council for International Organizations of Medical Sciences (CIOMS), 2004, SMQS DEV RAT US STAN
  • [6] Exploitation of semantic methods to cluster pharmacovigilance terms
    Dupuch, Marie
    Dupuch, Laetitia
    Hamon, Thierry
    Grabar, Natalia
    [J]. JOURNAL OF BIOMEDICAL SEMANTICS, 2014, 5
  • [7] Performance of the Standardised MedDRAA® Queries for Case Retrieval in the French Spontaneous Reporting Database
    Geniaux, Helene
    Assaf, Denise
    Miremont-Salame, Ghada
    Raspaud, Benedicte
    Gouverneur, Amandine
    Robinson, Philip
    Pariente, Antoine
    Salvo, Francesco
    [J]. DRUG SAFETY, 2014, 37 (07) : 537 - 542
  • [8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2013, UND MEDDRA MED DICT
  • [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2015, MEDDRA DAT RETR PRES
  • [10] Li X, 2013, COMP SCI S